Abstract:Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest in understanding how to optimize the use of our existing classes of bronchodilator and in identifying novel classes of bronchodilator drugs. However, new classes of bronchodilator have proved challenging to develop because many of these have no better efficacy than existing classes of bronchodilator and often have unacceptable safety profiles. Recent research has shown that optimization of bronchodilation occurs when both arms of the autonomic nervous system are affected through antagonism of muscarinic receptors to reduce the influence of parasympathetic innervation of the lung and through stimulation of β 2-adrenoceptors (β 2-ARs) on airway smooth muscle with β 2-AR-selective agonists to mimic the sympathetic influence on the lung. This is currently achieved by use of fixed-dose combinations of inhaled long-acting β 2-adrenoceptor agonists (LABAs) and long-acting muscarinic acetylcholine receptor antagonists (LAMAs). Due to the distinct mechanisms of action of LAMAs and LABAs, the additive/synergistic effects of using these drug classes together has been extensively investigated. More recently, so-called "triple inhalers" containing fixed-dose combinations of both classes of bronchodilator (dual bronchodilation) and an inhaled corticosteroid in the same inhaler have been developed. Furthermore, a number of so-called "bifunctional drugs" having two different primary pharmacological actions in the same molecule are under development. This review discusses recent advancements in knowledge on bronchodilators and bifunctional drugs for the treatment of asthma and COPD. SIGNIFICANCE STATEMENT: Since our last review in 2012, there has been considerable research to identify novel classes of bronchodilator drugs, to further understand how to optimize the use of the existing classes of bronchodilator, and to better understand the role of bifunctional drugs in the treatment of asthma and chronic obstructive pulmonary disease.

Olodaterol hydrochloride, a long-acting bronchodilator

Research progress of roflumilast in the treatment of chronic obstructive pulmonary disease

A long-acting bronchodilator——tiotropium bromide

A Novel Ultra Long-Acting Bronchodilator——indacaterol

A novel long-actingβ2-adrenoceptor agonist-indacaterol

Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.

Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs

Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

Current and novel bronchodilators in respiratory disease

Lung Function and Long-Term Safety of Tiotropium/olodaterol in East Asian Patients with Chronic Obstructive Pulmonary Disease.

Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.

Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD

Applications and Advancements of Tiotropium Bromide in Treatment of Chronic Obstructive Pulmonary Disease

Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium

Clinical research on bambuterol solution and tablet

The Identification of Indacaterol As an Ultralong-Acting Inhaled Beta(2)-Adrenoceptor Agonist

The efficacy and safety of tiotropium/olodaterol fixed?dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2

Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma

Discovery of a Highly Selective β 2 -Adrenoceptor Agonist with a 2-Amino-2-phenylethanol Scaffold as an Oral Antiasthmatic Agent

Pharmacology and Therapeutics of Bronchodilators Revisited

Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function